Bristol-Myers Squibb Company (NYSE:BMY) is among the 15 Best Passive Income Stocks to Buy Right Now. Scotiabank initiated coverage on BMY with a Sector Perform rating and a $45 price target. In Q3 2025, BMY reported revenue of $12.22 billion, a 2.77% increase from last year, exceeding analyst estimates by $422.1 million.

CEO Christopher Boerner announced an increase in full-year revenue guidance by $750 million to a range of $47.5 billion to $48 billion. Bristol-Myers Squibb expects gross margins to remain around 72% and operating expenses projected at $16.5 billion. Legacy portfolio sales are anticipated to decline 15%–17% for the year.

Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, and manufactures innovative medicines to treat serious diseases. While BMY shows investment potential, certain AI stocks offer greater upside potential and less downside risk. Investors can explore an undervalued AI stock that may benefit from current trends.

For more investment opportunities, explore 5 Extreme Dividend Stocks to Buy According to Hedge Funds and 15 Overlooked Dividend Stocks to Buy Right Now. Disclosure: None.

Read more at Yahoo Finance: Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target